SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza vaccine (FLUAD) at IDWeek in San Francisco (October 5-6). Results from five different studies...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]h-annual-idweek-300724074.html